14 August 2017
Visiongain’s new report World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography indicates that the global Bio-MEMS & Microfluidics market will see over $2.8bn in revenue in 2017.
The lead analyst of the report said:
“Micro-electro mechanical systems (MEMS) refers to the technology of microscopic devices, in particular, those with mechanical parts. Bio-MEMS therefor refer to the microscopic devices and microfabrication technologies which are suitable for biological applications. Microfluidics instead deals with the operation, performance and exact control of fluids which are constrained to a small (sub-millimeter) scale. These systems are broadly used for biological and biomedical purposes. In addition, bio-MEMS are also used for clinical diagnostics and research and development in the healthcare sector for numerous applications. For instance, the introduction of accelerometers in pacemakers have revolutionized the treatment of cardiac diseases. Further, using bio-MEMS devices there is a possibility of improving the delivery of transdermal drugs, which are currently limited to passive diffusion devices.
Rising demand to treat critically ill patients and use of artificial limbs and the treatment nerve problems have been a major factor for the growth of bio MEMS market. Uptake of microfluidics in a wide range of biomedical applications for diagnostic and analytical purposes as well as enhanced detection of pathogens and viruses using bio-MEMS are other major factors influencing the growth of this market. In addition, complex manufacturing procedures for MEMS and sophisticated fabrication techniques has been a core restraint for the growth of this market. Furthermore, the expensive nature of this technology and its reliance on a technologically advanced medical infrastructure has made adoption of bio-MEMS comparatively more difficult. Hence, some governments are introducing new reimbursement programs and increasing healthcare infrastructure to allow for these new technologies to become more widely adopted. This is creating more lucrative opportunities for top players to invest in emerging economies such as China and India.
The global bio-MEMS and microfluids market is segmented based on type, application and end user. Based on type the market is classified into implantable bio-MEMS, injectable bio-MEMS, and other devices. Further, based on application the market is classified into diagnostics, therapeutics, tissue engineering and others. Furthermore, based on end user it is segmented for the pharmaceutical industry, hospitals, research centres and others. ”
The 206-page report contains 204 tables, charts and graphs that add visual analysis in order to explain developing trends within the Bio-MEMS & Microfluidics market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Bio-MEMS & Microfluidics software submarkets, segmented by type, including forecasts for Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters and Micro Motors. The market is also segmented by application, with forecasts for Diagnostic, Therapeutic and Tissue Engineering from 2017-2027. In addition, the Bio-MEMS & Microfluidics market is segmented by end-user, with forecasts for Pharmaceutical Industry, Hospitals, Research Centres.
The 206-page report offers market forecasts and analysis for 7 key regional and 17 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Bio-MEMS & Microfluidics field in detail.
The World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography report will be of value to anyone who wants to better understand the Bio-MEMS & Microfluidics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Bio-MEMS & Microfluidics industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.